Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879570 | 1.00 | NFE2L2 (0.52) | NFE2L2GRM4PTGS1KDM1AIP6K1 | |
| SCHEMBL7970830 | 0.89 | LOXL2 (0.45) | NFE2L2GRM4KDM1AHDAC1HDAC6 | |
| SCHEMBL7970832 | 0.89 | LOXL2 (0.45) | NFE2L2GRM4KDM1AHDAC1HDAC6 | |
| SCHEMBL12185927 | 0.85 | KDM1A (0.55) | GRM4KDM1ANQO2APP | |
| SCHEMBL12185880 | 0.85 | NQO2 (0.50) | NFE2L2PTGS1KDM1ANQO2ALOX5 | |
| SCHEMBL29905751 | 0.84 | KDM1A (0.57) | NFE2L2GRM4PTGS1KDM1AIP6K1 | |
| SCHEMBL4056984 | 0.81 | PTGS1 (0.53) | NFE2L2GRM4PTGS1KDM1AIP6K1 | |
| SCHEMBL4056989 | 0.81 | PTGS1 (0.53) | NFE2L2GRM4PTGS1KDM1AIP6K1 | |
| SCHEMBL2641826 | 0.80 | CYP1A2 (0.61) | NFE2L2PTGS1KDM1ANQO2ALOX5 | |
| SCHEMBL2641860 | 0.80 | KCNH2 (0.50) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | NFE2L2 1785/4885GRM4 461/4885PTGS1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.